Contract Pharma Manufacturing News

  1. Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery 5/12/2026

    Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.

  2. Shilpa Medicare Enters Strategic Partnership With NXI Therapeutics AG 5/12/2026

    Shilpa Medicare Limited , a global integrated pharmaceutical and CDMO company, today announced the signing of a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland.

  3. Arvinas And Pfizer Enter Into A Transaction With Rigel Pharmaceuticals For The Exclusive Global Rights Of VEPPANU (vepdegestrant) 5/12/2026

    Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, for the exclusive global development, manufacturing, and commercialization rights for VEPPANU (vepdegestrant).

  4. Bora Group To Acquire MacroGenics' GMP Manufacturing Operations For $122.5M, Securing Maryland-Based Drug-Substance Facility And Existing Commercial Orders To Scale The Group's Integrated Technology Platform 5/12/2026

    Bora Pharmaceuticals today announced that its Board of Directors has approved the acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc, for total consideration of US$122.5M, subject to customary working capital adjustments, and a contingent consideration of up to $5M based on future customer orders.

  5. Africa CDC And Aspen Advance Long-Term Vaccine Supply Partnership For Africa 5/12/2026

    Africa Centres for Disease Control and Prevention (Africa CDC) and Aspen Pharmacare are in advanced discussions on a long-term demand and supply alignment framework aimed at strengthening sustainable vaccine manufacturing in Africa.

  6. ProBio And Curocell Achieve Key CAR-T Milestone With BLA Regulatory Approval And Commercial Readiness 5/11/2026

    Given the accelerating global momentum in CAR-T and gene therapies, ProBio Inc. and Curocell have achieved a significant milestone with the BLA regulatory approval and commercial readiness of Anbalcabtagene autoleucel (Anbal-cel; code: CRC01).

  7. Vector Science & Therapeutics Enters Three-Year Development And Manufacturing Agreement With MPP Group LLC 5/11/2026

    Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that it has entered into a development and manufacturing agreement with MPP Group LLC ("MPP"), a Mequon, Wisconsin-based contract development and manufacturing organization, to develop and manufacture pharmaceutical-grade peptides and to manufacture drug delivery devices developed by Vector.

  8. AGC Biologics Joins Orphan Therapeutics Accelerator's Clinical Development Network As A Manufacturing Partner To Advance Cell And Gene Therapies For Ultra-Rare Diseases 5/11/2026

    Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling commercial access to stalled rare disease treatments, today announced that AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has joined OTXL’s Clinical Development Network (Orphan ClinDevNet) as a manufacturing partner.

  9. 3PBIOVIAN Strengthens Its End-To-End CDMO Offering With State-Of-The-Art Sterility Testing, From Clinical To Commercial 5/7/2026

    3PBIOVIAN has significantly strengthened its sterility testing capabilities, reinforcing its position as an integrated, end-to-end CDMO serving biopharma customers from early development through commercial supply.

  10. Halozyme Announces Global Collaboration And License Agreement With GSK To Develop Subcutaneous Formulations Of Multiple Promising Oncology Targets 5/7/2026

    Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK.